Post Profile






What is the Difference Between Relapsing and Progressive MS?

  Althought replasing and primary progressive multiple sclerosis may be very similar, each form of the disease has its own peculiarities. MORE: Three tips for newly diagnosed multiple sclerosis patients In this interview from MSWorld at ACTRIMS Forum 2016, Dr. John Schafer, Director of the Mercy MS Center in Sacramento, California, talks to Dr. Daniel Kantor about the […] The post What is the Difference Between Relapsing and Progressive MS? appeared first on Multiple Sclerosis News Today.
read more

share

Related Posts


FDA Approves Ocrevus as 1st MS Treatment for Both Relapsing and Primary Progressive Forms

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

At long last, and for the first time in medical history, people with both relapsing and primary progressive forms of multiple sclerosis have reason to celebrate. The U.S. Food and Drug Administration (FDA) today approved Ocrevus (oc...

‘Adequate and Rapid Delivery’ of Ocrevus Expected, Says Genentech Director in Interview

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Ocrevus (ocrelizumab), now approved for both relapsing and primary progressive multiple sclerosis (MS), is expected to become available in the coming week. While patients and neurologists are waiting, Multiple Sclerosis News Today s...

Genentech to Report on Ocrevus Success in Reducing Disease Progression in Relapsing and Primary Progressive MS at EAN Congress

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Ocrevus (ocrelizumab) significantly reduces disease activity and disability progression in patients with relapsing multiple sclerosis (MS) and primary progressive MS (PPMS), according to results of post-hoc analyses of Genentech’s P...

#ACTRIMS2018 – Relapsing MS Patients With Impaired Vision Improved on Ocrevus, Updated Trial Data Show

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Ocrevus (ocrelizumab) improved vision among relapsing multiple sclerosis (MS) patients who participated in the Phase 3 clinical trials of the treatment, according to updated analyses recently presented at the Americas Committee for ...

MS Trust Seeking PPMS Patients’ Views on Ocrevus as It Tries to Obtain British Coverage

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Britain’s Multiple Sclerosis Trust is asking patients to help them get the National Health Service to cover Ocrevus (ocrelizumab) as a treatment for primary progressive multiple sclerosis, or PPMS. The key step is trying to persuade...

Comments


Copyright © 2016 Regator, LLC